|
| Mouse CLEC4A/DCIR Protein (LTP10324) |
|
| LTP10324 |
|
| 100ug |
|
|
$406 In stock |
| Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy. |
| Recombinant Mouse CLEC4A/DCIR Protein is expressed from Expi293 with hFc tag at the C-terminal. It contains Gln70-Leu238. |
|
| CLEC4A/DCIR |
|
| Mouse |
|
| Q9QZ15 |
|
| Gln70-Leu238 |
|
| The protein has a predicted MW of 46.3 kDa. Due to glycosylation, the protein migrates to 60-65 kDa based on the Tris-Bis PAGE result. |
|
| 0 |
|
| C-hFc |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
